trending Market Intelligence /marketintelligence/en/news-insights/trending/GL4QkagkPcjC8B2Xil7sTQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Chi-Med amends cancer drug agreement with Eli Lilly to garner more sales royalty

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Chi-Med amends cancer drug agreement with Eli Lilly to garner more sales royalty

Hutchison China MediTech Ltd. amended its license agreement on cancer drug fruquintinib with Eli Lilly and Co. to garner more sales royalty.

The Hong Kong-based company, backed by billionaire Li Ka-shing, will receive 15% to 29% royalty payment on fruquintinib's sales in China, instead of the 15% to 20% range set in 2013.

The amendment also shifts the planning, execution and decision making responsibility of drug indication development in China to Chi-Med. Eli Lilly, which took the main responsibility for the development according to the 2013 agreement, will pay $20 million for each fruquintinib indication approved in China, up to three indications, as Chi-Med will pay for all of the development costs in the country.

Fruquintinib, approved by Chinese regulator as a treatment for colorectal cancer in September, is an oral inhibitor that targets vascular endothelial growth factor receptors, or VEGFR, to fight disease. The drug is marketed under the Elunate name in China.

The drug in November, however, failed a late-stage study as a treatment for lung cancer and is still under trial as a therapy for gastric cancer. The Hong Kong-based company has then been exploring combo cancer treatments for the drug, including combinations with Innovent Biologics Inc.'s sintilimab, Genor BioPharma Co. Ltd.'s genolimzumab, Shanghai Junshi Biosciences Co. Ltd.'s toripalimab and Taizhou Hanzhong Pharmaceuticals Inc's monoclonal antibody HX008.

Sintilimab, genolimzumab, toripalimab and HX008 are all PD-1 class of checkpoint inhibitors that work by blocking the interaction between certain proteins on the surface of immune cells and cancer cells to enable the immune system to target the disease.